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Abstract
In 2001, the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis) trial demonstrated a 6.1%
absolute decrease in mortality in patients with severe sepsis. Recombinant human activated protein C was subsequently licensed for use
by both the US Food and Drug Administration and the European Medicines Evaluation Agency. There has been some controversy over
aspects of the original study protocol, and subsequent trials have raised concerns about both the efﬁcacy and the side effect proﬁle
of recombinant human activated protein C. Signiﬁcant doubt remains as to the role of recombinant human activated protein C in the
management of severe sepsis, and this review aims to summarize the evidence both for and against its use.
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Introduction
Severe sepsis is an increasingly common condition that is
associated with high levels of morbidity and mortality that
place a large burden upon healthcare resources throughout
the world. In the USA, severe sepsis accounts for approxi-
mately 215 000 deaths annually, equal to the number of
deaths from myocardial infarction, with estimated annual
costs of $16.7 billion [1]. The incidence of sepsis has
increased over the past two decades [2] and, with an ageing
population, is likely to continue to rise. Despite many
advances in critical care over the years, the level of mortality
due to sepsis remains high, and although there has been a
modest reduction in the mortality rate, the actual number of
deaths due to severe sepsis continues to rise [2]. Further-
more, for those who do survive, quality of life is frequently
signiﬁcantly diminished [3].
In 2001, the PROWESS trial of recombinant human acti-
vated protein C (APC) (drotrecogin alfa activated, hereafter
referred to simply as drotrecogin alfa) for severe sepsis
reported a 6.1% absolute reduction in mortality and a 19.4%
relative reduction in the risk of mortality at 28 days [4].
Since the publication of the results of this trial, there has
been, and continues to be, much debate over the efﬁcacy
and safety of this expensive therapy.
The Pathophysiology of Sepsis and the Role
of APC
Sepsis is the systemic response by a host organism to inva-
sion by a pathogenic microorganism, resulting in activation of
inﬂammatory and coagulation pathways and inhibition of ﬁbri-
nolysis. The dysregulation of these pathophysiological mecha-
nisms signiﬁcantly contributes to the organ dysfunction
observed in severe sepsis.
The initial response by the host to invasion by a patho-
genic microorganism is initiated by toll-like receptors, which
are pattern recognition receptors that recognize speciﬁc cell
wall molecules within bacterial, viral and fungal cell walls [5].
It is in response to recognition of the microbial pathogen by
the toll-like receptors that the complex host immune
response is triggered. Initially, proinﬂammatory mediators
such as interleukin-1, interleukin-6, tumour necrosis factor
alpha, nitric oxide, prostaglandins and other acute-phase pro-
teins are released. Among other activities, these mediators
induce leukocytes, upregulate tissue factor, and activate the
coagulation pathways. Concurrently, there is depletion of
endogenous anticoagulants such as antithrombin, heparin and
APC, as well as inhibition of normal ﬁbrinolysis. The activa-
tion of the coagulation cascade, together with depletion of
endogenous anticoagulants and impaired ﬁbrinolysis, results
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in the generation of thrombi within the microcirculation,
which can lead to tissue hypoxia and organ dysfunction.
Following the initial marked inﬂammatory response to
sepsis, there is a sustained anti-inﬂammatory or immunosup-
pressive status. A major inﬂammatory control mechanism
during this phase is apoptosis of immune effector cells such
as B-lymphocytes, T-lymphocytes, and dendritic cells. There
are two main mechanisms by which apoptosis impairs the
immune response. The ﬁrst mechanism leads to a profound
decrease in B-cell and T-cell numbers, resulting in impair-
ment of the adaptive immune response. This also impairs the
innate immune response because of important cross-talk that
occurs between the innate and adaptive immune systems [6].
The second mechanism by which apoptosis results in
immune dysfunction is induction of immune unresponsive-
ness, or anergy, in the surviving immune cells. Clinical studies
of patients with sepsis demonstrate that the degree of apop-
tosis of circulating lymphocytes correlates with the severity
of sepsis and predicts fatal outcome in septic shock, suggest-
ing the importance of apoptosis as a biomarker [7–9].
Given the extent of the problem that sepsis poses, it is of
little surprise that much time and many resources have been
invested in searching for treatments for this devastating con-
dition. Given that the initial trigger appears to be overstimu-
lation of the inﬂammatory cascade and resulting coagulation
dysfunction, many agents targeting speciﬁc mediators of the
inﬂammatory and coagulation cascades have been investi-
gated. Some agents studied include corticosteroids, tumour
necrosis factor antagonists, interleukin-1 antagonists, anti-
endotoxin antibodies, and antithrombin. Unfortunately, none
has led to improvement in survival rates, and, indeed, in
some situations, they may even cause harm [10].
APC
APC is an endogenous protein that acts as an important
modulator of both the inﬂammatory and coagulatory
responses associated with severe sepsis. APC has anticoagu-
lant, anti-inﬂammatory, pro-ibrinolytic and antiapoptotic
effects. Several studies have shown that low levels of circu-
lating protein C are associated with increased morbidity and
mortality [11–13]. In addition to baseline levels of protein C,
early changes in protein C levels are also predictive of out-
come in patients with severe sepsis [14]. Protein C is acti-
vated on the endothelial surface by the thrombin–
thrombomodulin complex to yield APC. APC inactivates
factor Va and factor VIIIa, thereby blocking the ampliﬁcation
of the coagulation system; this process is accelerated by the
cofactor protein S. APC has anti-inﬂammatory effects, by
inhibiting the formation of tumour necrosis factor, interleu-
kin-6, and interleukin-8 , as well as by inhibiting neutrophil
chemotaxis. APC promotes ﬁbrinolysis by binding and inhib-
iting plasminogen activator inhibitor-1, a potent antiﬁbrinolyt-
ic factor, and hence acts indirectly as a proﬁbrinolytic agent.
Finally, APC has also been shown to possess antiapoptotic
properties, and this mechanism has been shown to be neuro-
protective in stroke models [15,16]. These properties differ
from those of tissue factor pathway inhibitor and antithrom-
bin, two other anticoagulants, both of which failed to reduce
mortality in large trials in severe sepsis [17,18].
In 2001, the results of the PROWESS trial were published.
It was a randomized, double-blind, placebo-controlled, multi-
centre trial involving 164 centres in 11 countries. It enrolled
1690 patients with severe sepsis of less than 24 h duration
to receive either drotrecogin alfa or placebo. There was a
large number of exclusion criteria, mainly aimed at reducing
the risk of excessive bleeding.
There was good adherence to the study protocol, and the
patients were heterogeneous. Enrolment was stopped early
at the second interim analysis, because the difference in mor-
tality rates between the two groups exceeded the a priori
guideline for stopping the trial. Drotrecogin alfa was associ-
ated with a 19.4% reduction in the relative risk of death and
an absolute reduction in the risk of death of 6.1% (p 0.005).
The incidence of serious bleeding showed a trend towards
being higher in the drotrecogin alfa group (3.5% vs. 2.0%;
p 0.06) [4].
Given the high purchase cost of the drug and the poten-
tially large eligible patient group, the healthcare resource
implications were huge, and triggered subgroup analyses of
the PROWESS dataset, with a view to targeting those who
may most beneﬁt from drotrecogin alfa. Notwithstanding the
inherent difﬁculties of post hoc subgroup analysis, it was not
shown that the groups with the most severe disease, accord-
ing to either APACHE II score (Table 1) or number of organ
failures (Table 2), received the largest beneﬁt from treatment
with drotrecogin alfa [19].
In November 2001, the US Food and Drug Administration
(FDA) approved the use of drotrecogin alfa for those with an
APACHE II score ‡25. In 2002, the European Medicines Eval-
uation Agency (EMEA) approved its use for those with multi-
ple organ failure. The FDA mandated that studies be
undertaken to further evaluate the efﬁcacy and safety of
drotrecogin alfa in certain patient groups, including those with
severe sepsis and a low risk of death, and paediatric popula-
tions. The FDA also mandated a study to investigate medium-
term survival of those enrolled in the PROWESS trial.
The Administration of Drotrecogin Alfa (activated) in
Early Stage Severe Sepsis (ADDRESS) Study [20] attempted
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to recruit 11 000 patients with severe sepsis and a low risk
of death, as deﬁned by an APACHE II score <25 or single-
organ failure. Enrolment in this trial was terminated early,
after 2640 patients, because of low likelihood of efﬁcacy. In
addition, the rate of serious bleeding events was higher in
the drotrecogin alfa group than in the placebo group (3.9%
vs. 2.2%; p 0.01). These data, combined with the PROWESS
data, provide strong support for the statement that drotr-
ecogin alfa should not be used for patients with severe sepsis
and a low risk of death. Further analysis of those who had
single-organ failure and recent surgery (within the preceding
30 days) revealed that patients treated with drotrecogin alfa
had statistically signiﬁcantly higher mortality than the placebo
group, a ﬁnding substantiated upon review of the same sub-
set in the PROWESS study.
The RESOLVE study looked at the efﬁcacy and safety of
drotrecogin alfa in children. The study failed to demonstrate
efﬁcacy of drotrecogin alfa in children with severe sepsis.
Although the overall incidences of adverse events and seri-
ous bleeding events were similar between the two groups,
there were numerically more instances of central nervous
system bleeding in the drotrecogin alfa group, particularly in
children less than 60 days old [21].
A study to determine the medium-term survival of the
subjects with severe sepsis who were enrolled in the
PROWESS trial showed that there was no signiﬁcant
improvement in mortality at any time up to 1 year, except at
the 28-day time-point (the primary outcome time-point in
PROWESS). Again, accepting the limitations, post hoc analysis
was undertaken, and showed that those with an APACHE II
score ‡25 who were treated with drotrecogin alfa had a bet-
ter overall duration of survival and higher landmark survival
at 3 months, 6 months, 1 year and 2.5 years. For those sub-
jects with an APACHE II score of <25, there was a signiﬁ-
cant decrease in landmark survival at 1 year in those who
received drotrecogin alfa (p 0.04), but no difference at other
time-points [22].
Controversies in the Use of APC
Since the original publication of the PROWESS trial, there has
been, and continues to be, much debate about the use of
drotrecogin alfa. There remains some unease in some quarters
of the clinical and scientiﬁc communities about its use, particu-
larly with regard to the original study protocol and the efﬁcacy
and safety proﬁle of drotrecogin alfa [23–25].
Debate has centred on protocol changes during the origi-
nal PROWESS study. In the early stages of the trial, an exter-
nal evaluation committee advised that a large number of
patients who were recruited had a high risk of death from
causes other than sepsis. The protocol was amended after
720 patients had been recruited prior to the ﬁrst interim
analysis to exclude such subjects, resulting in patients with
less severe comorbidity and more acute infectious disease. In
addition, at approximately the same time, a new master cell
bank was introduced, from which the drotrecogin alfa was
manufactured. Both Eli Lilly and the FDA performed exten-
sive tests on both batches of drotrecogin alfa, and no signiﬁ-
cant differences were found. Following these changes, the
reduction in mortality associated with treatment with drotr-
ecogin alfa was greater than it had been up to that point
(Table 3).
The apparent improvement in efﬁcacy could be due to a
number of potential factors, including different patient
populations, undetectable changes in the drug, chance, or a
TABLE 1. Mortality outcomes in sub-
groups according to APACHE II score
and treatment effect in PROWESS
Population








1st (3–19) 33/218 (15.1) 26/215 (12.1) )3.0 1.25 (0.27–2.02)
2nd (20–24) 49/218 (22.5) 57/222 (25.7) 3.2 0.88 (0.63–1.22)
3rd (25–29) 48/204 (23.5) 58/162 (35.8) 12.3 0.66 (0.48–0.91)
4th (30–53) 80/210 (38.1) 118/241 (49.0) 10.9 0.78 (0.63–0.96)
APACHE II (higher vs. lower)
1st/2nd quartiles 82/436 (18.8) 83/437 (19.0) 0.2 0.99 (0.75–1.30)
3rd/4th quartiles 128/414 (30.9) 176/403 (43.7) 12.8 0.71 (0.59–0.85)
TABLE 2. Subgroups according to number of organ failures
and response to treatment in PROWESS
Population







Number of organ dysfunctions
1 42/216 (19.4) 43/203 (21.2) 1.8 0.92 (0.63–1.34)
2 56/270 (20.7) 71/274 (25.9) 5.3 0.80 (0.59–1.08)
3 56/214 (26.2) 75/217 (34.6) 8.4 0.76 (0.57–1.02)
‡4 56/150 (37.3) 70/146 (47.9) 10.6 0.78 (0.60–1.02)
Single vs. multiple organ dysfunction
1 42/216 (19.4) 43/203 (21.2) 1.8 0.92 (0.63–1.34)
‡2 168/634 (26.5) 216/637 (33.9) 7.4 0.78 (0.66–0.93)
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combination of these three factors. The FDA thoroughly inves-
tigated this in their review, and concluded that ‘‘The p value for
the interaction between the trial results pre- and post-amend-
ment is 0.08. While this p value suggests that the impact of
changes in the trial should be looked into, it is also not inconsis-
tent with chance variation. Analyses of various factors that
might have led to outcome differences between the trial halves
did not support concerns that any of the factors likely
accounted for these differences. We have therefore concluded
that the differences most likely did arise by chance’’ [19].
The use of the APACHE II scoring system in the trial has
also been questioned [10]. The APACHE II is a severity of
disease scoring system that combines physiological data with
information on age and comorbidity as well as diagnosis [26].
It was designed and validated to predict mortality based on
data from the ﬁrst 24 h of intensive-care unit care, and is
not seen as having appropriate accuracy to allow individual
prognostication or indeed to guide therapy for individual
patients. In addition, as an APACHE II score also takes into
account other risk factors for death, such as age and comor-
bidity, the effect of using an APACHE II score to determine
treatment would be to introduce bias against the elderly and
chronically inﬁrm. Despite the limitations of using
APACHE II scores to decide upon individual treatment, an
APACHE II score was shown to be the best discriminator of
death in the PROWESS trial (Table 1), and was recom-
mended by the FDA for the identiﬁcation of high-risk
patients with severe sepsis.
As shown above, the efﬁcacy demonstrated by drotreco-
gin alfa in the PROWESS trial has not been reproduced in
subsequent randomized controlled trials in paediatric popula-
tions or in those with sepsis and a low risk of death [20,21].
A post hoc subgroup analysis of the small (321) number of
patients included in the ADDRESS study with an APACHE II
score ‡25 failed to show beneﬁt of drotrecogin alfa. The
mortality rate was higher, albeit not statistically signiﬁcantly,
among the group receiving drotrecogin alfa than in the pla-
cebo group (29.5% vs. 24.7%). Again, this was a post hoc sub-
group analysis, with all of the inherent limitations associated
with this. It should be noted that, when compared with
those of the PROWESS study, these subjects had a lower
mean APACHE II score, and their mortality rate was signiﬁ-
cantly lower than the 43.7% observed in the placebo group
of the PROWESS study. This may simply reﬂect the fact that,
as intended by the design of the study, less severely ill
patients were enrolled in the ADDRESS study, which also
demonstrates some of the inherent limitations of using
APACHE II scores to predict outcome in individual patients.
Concerns regarding the increased incidence of serious
bleeding events also persist. A large, multicentre, multina-
tional, non-randomized, open-label trial of drotrecogin alfa
involving 2378 patients (the ENHANCE trial), which
had inclusion and exclusion criteria similar to those of
PROWESS, was able to demonstrate 28-day mortality similar
to that achieved in PROWESS, but also had a higher
incidence of serious bleeding events (6.5% vs. 3.5%). The
authors speculate that there may have been a higher back-
ground bleeding rate in the subjects of this study. They have
based this speculation on the increased incidence of post-
infusion bleeding (3.2% vs. 1.2%) ‘‘presumably when the
drotrecogin alfa infusion effect would be gone’’, coupled with
the higher number of surgical patients and the higher haema-
tological and hepatic SOFA scores in these subjects. This
same study also showed that patients with severe sepsis
treated with drotrecogin alfa within the ﬁrst 24 h of their
organ dysfunction exhibited lower mortality, regardless of
disease severity, and the authors suggested that time to
treatment could be assessed in future trials [27].
To Which Patients should Drotrecogin Alfa
be Targeted?
It can be said with relative certainty that the following
groups should not receive drotrecogin alfa:
1 Children
2 Patients with severe sepsis and a low risk of death
3 Patients with severe sepsis and single-organ failure
4 Patients with exclusion criteria matching those of the ori-
ginal PROWESS study, including those who underwent
major surgery within the preceding 12 h.
Given the uncertainty of the beneﬁt of this expensive therapy,
coupled with the increased risk of serious bleeding events, the
decision concerning who should receive treatment remains dif-
ﬁcult. Currently, there is no consensus on this matter within
the critical-care community. Both the FDA and the EMEA rec-
ommend that drotrecogin alfa be used only in patients at high
risk of death due to sepsis. The FDA speciﬁed an APACHE II
score of ‡25 and the EMEA speciﬁed acute multi-organ failure,
when therapy can be started within 24 h of the onset of organ











Before amendment 720 30 28 0.94 0.57
After amendment 970 31 22 0.71 0.001
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failure. Others have sensibly suggested that the decision should
be made by experienced clinicians, taking into consideration all
the clinical data, to assess the chances of improved survival vs.
the risk of serious bleeding [28,29]. Although this is a sensible
suggestion, we do know that the ability of critical-care doctors
to predict the risk of death is limited [30]. A recently published
review by the Cochrane Collaboration concluded that ‘‘there
was no evidence suggesting that drotrecogin alfa should be used
for treating patients with severe sepsis or septic shock. Addi-
tionally, drotrecogin alfa seems to be associated with a higher
risk of bleeding. Unless additional RCT’s provide evidence of a
treatment effect, policy-makers, clinicians and academics should
not promote the use of drotrecogin alfa’’ [31].
It is of interest for the future that research looking at
chemically altering the APC molecule to alter its anticoagu-
lant effects, while maintaining its anti-inﬂammatory effects,
has recently been instigated, but this is still at a very early
stage of development [32].
Conclusions
Drotrecogin alfa remains the only drug that has been proven
in a well-conducted randomized controlled trial to decrease
mortality in patients with severe sepsis. Despite this, further
studies have raised concerns regarding both the efﬁcacy and
the side effect proﬁle of this agent, such that signiﬁcant
doubt exists as to its role in the management of severe sep-
sis. A study of plasma APC levels, drotrecogin alfa dose and
outcome is underway. In addition, a further randomized trial
is currently underway that is attempting to demonstrate
whether patients can be prospectively identiﬁed and beneﬁt
from treatment with drotrecogin alfa. Following these trials,
we will hopefully have clearer evidence of its usefulness in
this devastating condition. Until then, clinicians should use
this drug only after careful consideration of the risks and
beneﬁts.
Transparency Declaration
G. Houston declares no competing interests. B. H. Cuthbert-
son has received consulting fees, grant support and lecture
fees from Eli Lilly and Co.
References
1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J,
Pinsky MR. Epidemiology of severe sepsis in the United States. Anal-
ysis of incidence, outcome, and associated costs of care. Crit Care
Med 2001; 29: 1303–1310.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sep-
sis in the United States from 1979 through 2000. N Engl J Med 2003;
16: 1546–1554.
3. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA. Long-
term health-related quality of life in survivors of sepsis. Short
Form 36: a valid and reliable measure of health-related quality of life.
Crit Care Med 2000; 28: 3599–3605.
4. Bernard GR, Vincent JL, Laterre PF et al. Recombinant Human Pro-
tein C Worldwide Evaluation in Severe Sepsis (PROWESS) study
group. Efﬁcacy and safety of recombinant human activated protein C
for severe sepsis. N Engl J Med 2001; 10: 699–709.
5. Cinel I, Dellinger RP. Advances in pathogenesis and management of
sepsis. Curr Opin Infect Dis 2007; 20: 345–352.
6. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes:
understanding the role of innate and acquired immunity. Shock 2001;
16: 83–96.
7. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith
CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both
the death receptor and mitochondrial pathways. J Immunol 2005; 8:
5110–5118.
8. Le Tulzo Y, Pangault C, Gacouin A et al. Early circulating lymphocyte
apoptosis in human septic shock is associated with poor outcome.
Shock 2002; 18: 487–494.
9. Guisset O, Dilhuydy MS, Thiebaut R et al. Decrease in circulating
dendritic cells predicts fatal outcome in septic shock. Intensive Care
Med 2007; 33: 148–152.
10. Warren HS, Suffredini AF, Eichacker PQ, Munford RS. Risks and
beneﬁts of activated protein C treatment for severe sepsis. N Engl J
Med 2002; 13: 1027–1030.
11. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple
organ failure, and disseminated intravascular coagulation. compared
patterns of antithrombin III, protein C, and protein S deﬁciencies.
Chest 1992; 101: 816–823.
12. Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR. Low
levels of protein C are associated with poor outcome in severe
sepsis. Chest 2001; 120: 915–922.
13. Fijnvandraat K, Derkx B, Peters M et al. Coagulation activation and
tissue necrosis in meningococcal septic shock: severely reduced pro-
tein C levels predict a high mortality. Thromb Haemost 1995; 73: 15–20.
14. Shorr AF, Bernard GR, Dhainaut JF et al. Protein C concentrations
in severe sepsis: an early directional change in plasma levels predicts
outcome. Crit Care 2006; 10: R92.
15. Guo H, Liu D, Gelbard H et al. Activated protein C prevents neuro-
nal apoptosis via protease activated receptors 1 and 3. Neuron 2004;
4: 563–572.
16. Cheng T, Liu D, Grifﬁn JH et al. Activated protein C blocks p53-
mediated apoptosis in ischemic human brain endothelium and is neu-
roprotective. Nat Med 2003; 9: 338–342.
17. Abraham E, Reinhart K, Opal S et al. Efﬁcacy and safety of tifacogin
(recombinant tissue factor pathway inhibitor) in severe sepsis: a ran-
domized controlled trial. JAMA 2003; 2: 238–247.
18. Warren BL, Eid A, Singer P et al. Caring for the critically ill patient.
High-dose antithrombin III in severe sepsis: a randomized controlled
trial. JAMA 2001; 15: 1869–1878.
19. FDA clinical review drotrecogin alfa (activated) [recombinant
human activated protein C (rhAPC)] xigris. 2001. Approved: 21
November 2001. Available at: http://www.fda.gov/cder/biologics/
review/droteli112101r1.pdf
20. Abraham E, Laterre PF, Garg R et al. Administration of Drotrecogin
Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study
Group. Drotrecogin alfa (activated) for adults with severe sepsis and
a low risk of death. N Engl J Med 2005; 13: 1332–1341.
CMI Houston and Cuthbertson Activated protein C for the treatment of severe sepsis 323
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 319–324
21. Nadel S, Goldstein B, Williams MD et al. REsearching severe Sepsis
and Organ dysfunction in children: a gLobal perspective (RESOLVE)
study group. Drotrecogin alfa (activated) in children with severe sep-
sis: a multicentre phase III randomised controlled trial. Lancet 2007;
9564: 836–843.
22. Angus DC, Laterre PF, Helterbrand J et al. The effect of drotrecogin
alfa (activated) on long-term survival after severe sepsis. Crit Care
Med 2004; 32: 2199–2206.
23. Eichacker PQ, Natanson C. Recombinant human activated protein C
in sepsis: inconsistent trial results, an unclear mechanism of action,
and safety concerns resulted in labeling restrictions and the need for
phase IV trials [see comment]. Crit Care Med 2003; 1 (suppl): S94–S96.
24. Eichacker PQ, Danner RL, Suffredini AF, Cui X, Natanson C. Reas-
sessing recombinant human activated protein C for sepsis: time for
a new randomized controlled trial. Crit Care Med 2005; 33:
2426–2428.
25. Eichacker PQ, Natanson C. Increasing evidence that the risks
of rhAPC may outweigh its beneﬁts. Intensive Care Med 2007; 33:
396–399.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a
severity of disease classiﬁcation system. Crit Care Med 1985; 13:
818–829.
27. Vincent JL, Bernard GR, Beale R et al. Drotrecogin alfa (activated)
treatment in severe sepsis from the global open-label trial
ENHANCE: further evidence for survival and safety and implications
for early treatment. Crit Care Med 2005; 33: 2266–2277.
28. Dellinger RP. Recombinant activated protein C: the key is clinical
assessment of risk of death, not subset analysis. Crit Care 2006; 10:
114.
29. Bernard GR. Drotrecogin alfa (activated) (recombinant human acti-
vated protein C) for the treatment of severe sepsis [see comment].
Crit Care Med 2003; 1 (suppl): S85–S93.
30. Rocker G, Cook D, Sjokvist P et al. Clinician predictions of intensive
care unit mortality. Crit Care Med 2004; 32: 1149–1154.
31. Marti-Carvajal A, Salanti G, Cardona AF. Human recombinant acti-
vated protein C for severe sepsis [update of Cochrane Database
Syst Rev 2007;(3):CD004388; PMID: 17636755]. Cochrane Database
Syst Rev 2008; 1: 004388.
32. Bae JS, Yang L, Manithody C, Rezaie AR. Engineering a disulﬁde bond
to stabilize the calcium-binding loop of activated protein C elimi-
nates its anticoagulant but not its protective signaling properties.
J Biol Chem 2007; 12: 9251–9259.
324 Clinical Microbiology and Infection, Volume 15 Number 4, April 2009 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 15, 319–324
